Eli Lilly’s newest weight-loss drug relieved pain in patients with knee osteoarthritis

Eli Lilly’s newest weight-loss drug relieved pain in patients with knee osteoarthritisListen(2 min)Listen(2 min)One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis.The drug giant’s LLY stock was up about 1% in premarket trading Thursday after announcing the Phase 3 data for retatrutide, a GIP, GLP-1 and glucagon triple hormone receptor agonist that Lilly refers to as “triple G.”About the AuthorJaimy Lee is a healthcare reporter and editor for MarketWatch. She is based in New York.Copyright © 2025 MarketWatch, Inc. All rights reserved.